You are here: Home: BCU 9 | 2005: Breast Cancer Journal Club Notes


Journal of Clinical Oncology 2005;23(10):2155-61. Abstract


  • Evaluate efficacy and tolerability of capecitabine in older women with ABC Patients and methods
  • 73 patients (median age: 73 years old)
  • 30 patients received oral capecitabine 1,250 mg/m2 BID on days one to 14 every 21 days
    – Due to two toxic deaths, capecitabine 1,000 mg/m2 BID was administered to the remaining 43 patients


  • Dose reductions were required in 30 percent of patients in the standard dose group, but capecitabine was given without a dose reduction to 95% of patients in the low-dose group.
  • Capecitabine had a favorable safety profile.
    – Grade III/IV toxicities: ≤10 percent fatigue, diarrhea, dyspnea and nausea
  • Efficacy
    – 1,250 mg/m2 BID: response rate was 36.7 percent; 33 percent had disease stabilization at ≥24 weeks.
    – 1,000 mg/m2: response rate was 34.9 percent; 46 percent had prolonged disease stabilization. – Median time to disease progression was four months in both groups.


Balducci L et al. Management of breast cancer in the older woman. Cancer Control 2001;8(5):431-41. Abstract

Blum JL et al. Results of a phase II trial of combination therapy with oral capecitabine and weekly paclitaxel for metastatic breast cancer: Preliminary results in taxane pretreated women. San Antonio Breast Cancer Symposium 2005;Abstract 6091.

Blum JL et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer. Cancer 2001;92(7):1759-68. Abstract

Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17(2):485-93. Abstract

Di Costanzo F et al. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: Dose-finding trial of GOIRC and GOL. Ann Oncol 2005;[Epub ahead of print]. Abstract

El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005;14(5):368-74. Abstract

Fumoleau P et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40(4):536-42. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract

Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003;53(4):227-44. Abstract

Kara IO et al. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2005;[Epub ahead of print]. Abstract

Lee KS et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC). San Antonio Breast Cancer Symposium 2005;Abstract 5052.

Mavroudis D et al. A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report. San Antonio Breast Cancer Symposium 2005;Abstract 6089.

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

O’Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-f luorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract

Reichardt P et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14(8):1227-33. Abstract

Schott AF et al. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol 2005;[Epub ahead of print]. Abstract

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract

Tong DK et al. Phase II study of an ‘all-oral’ regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer — Safety, efficacy and quality of life. Oncology 2005;68(4-6):520-5. Abstract

Von Minckwitz G et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy — First results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio Breast Cancer Symposium 2005;Abstract 38.

Wagstaff AJ et al. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63(2):217-36. Abstract



Editor’s Note:
Cheetos and raisins for dinner: The curse of Wilma and why a public sector that can’t figure out a way to get electricity to gas stations seems unlikely to
be victorious in the “war on cancer”
Harold J Burstein, MD, PhD
- Select publications
Charles L Vogel, MD
- Select publications
Eleftherios P Mamounas, MD, MPH
- Select publications
Journal Club

Breast Cancer Journal Club Notes

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer

E2100: A Randomized Phase III Trial of Paclitaxel versus Paclitaxel Plus Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer (ABC) in Older Women

Fulvestrant versus Anastrozole for the Treatment of Advanced
Breast Carcinoma: A Prospectively Planned Combined Survival
Analysis of Two Multicenter Trials

Patterns of Care in Medical Oncology: A Case Survey Comparing Practices of Breast Cancer Investigators and General Oncologists — Section A: Adjuvant Endocrine Therapy


CME Information
Faculty Disclosures
Editor's Office